ClinicalTrials.gg
RecruitingNCT04929223Updated Nov 6, 2026

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

A Phase 1 interventional study of Inavolisib and Bevacizumab in Metastatic Colorectal Cancer, sponsored by Hoffmann-La Roche. Recruiting at 84 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years later.
Updated Nov 6, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
542
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
18th of 224
542 · median 63
Started
2021
with 6 others
Phase 1
26 of 230
5 open now
Primary completion
2030-08
later than 59 of 60 live
Registered
180th of 230
by date
Lead sponsor
22 of 230
Hoffmann-La Roche

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 18th largest by planned enrollment of the 224 interventional ones that give a count, is one of 7 that started in 2021, is one of 26 in phase 1, reaches primary completion later than 59 of the 60 other live ones, and was the 180th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • KRAS G12C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed cohort-specific Form
  • Age >= 18 years at time of signing Informed Consent Form
  • Biomarker eligibility as determined by:

    • A validated test approved by local health authorities for detection of the specified biomarkers/mutations.
    • A validated test performed at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA) -certified or equivalently accredited diagnostic laboratory using a validated test for detection of the specified biomarkers.
    • Prior test results completed before signing cohort-specific Informed Consent Form or local test results generated prior to or during screening, and availability of a full report of the testing results OR
    • Blood-based FoundationOne Liquid CDx biomarker eligibility test result generated prior to or during screening or, in case of re-enrollment after treatment discontinuation, prior to starting a new anti-cancer therapy.
  • (ECOG) Performance Status of \<= 1
  • >= 3 months, as determined by the investigator
  • confirmed adenocarcinoma originating from the colon or rectum
  • disease
  • Prior therapies for metastatic disease
  • Ability to comply with the study protocol, in the investigators judgment
  • (at least one target lesion) according to , Version 1.1 (RECIST v1.1)
  • Baseline tumor tissue samples will be collected from all participants for exploratory biomarker research
  • Adequate hematologic and organ function within 14 days prior to initiation of study treatment
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use measures
  • For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria

  • Current participation or enrollment in another interventional clinical trial. Participants who are participating in the follow-up period of an interventional clinical trial are eligible for the study.
  • Any systemic anti-cancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study treatment
  • Treatment with therapy within 28 days prior to initiation of study treatment
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study
  • Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety
  • Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  • Uncontrolled tumor-related pain
  • Uncontrolled or symptomatic hypercalcemia
  • and active liver disease
  • Negative test at screening, with the following exception: Participants with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a greater than or equal to 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months.
  • Symptomatic, untreated, or actively progressing
  • History of or carcinomatous meningitis
  • History of other than CRC within 2 years prior to screening, with the exception of malignancies with a negligible risk of or death
  • Any other disease, unresolved toxicity from prior therapy, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
  • Requirement for treatment with any medicinal product that contraindicates the use of any of the study treatments, may interfere with the planned treatment, affects participant compliance, or puts the patient at higher risk for treatment-related complications
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
542 participants (estimated)

Study arms

  • Experimental
    Inavolisib + Cetuximab

    Participants will receive 9 milligrams (mg) of inavolisib by mouth once daily (QD) on Days 8-28 of Cycle 1, then QD on Days 1-28 from Cycle 2 onwards (1 cycle=28 days). Participants will also receive cetuximab intravenous (IV) infusion 400 mg/m2 body surface area on Day 1 of Cycle 1. All subsequent weekly (QW) doses will be 250 mg/m2 each. This arm is closed.

    Drug: Inavolisib · Drug: Cetuximab · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Inavolisib + Bevacizumab

    Participants will receive 9 mg of inavolisib by mouth QD combined with bevacizumab 15 milligram/kilogram (mg/kg) IV once every three weeks (Q3W) on Day 1 of each cycle (1 cycle=21 days). This arm is closed.

    Drug: Inavolisib · Drug: Bevacizumab · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Atezolizumab + Tiragolumab + Bevacizumab

    Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle, combined with tiragolumab at a dose of 600 mg IV infusion on Day 1 of each cycle and bevacizumab IV infusion at a dose of 15 mg/kg on Day 1 of each cycle. (Cycle length=21 days) This arm is active, and not recruiting participants.

    Drug: Bevacizumab · Drug: Atezolizumab · Drug: Tiragolumab · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Atezolizumab + Tiragolumab

    Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle combined with tiragolumab 600 mg IV infusion on Day 1 of each cycle. (Cycle length=21 days) This arm is active, and not recruiting participants.

    Drug: Atezolizumab · Drug: Tiragolumab · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Atezolizumab + SY-5609

    Participants will receive 1680 mg of atezolizumab by IV infusion on Day 1 of each cycle Q4W in repeated 28-day cycles combined with SY-5609 at a dose of 3, 4, 5, 6, 7 or 10 mg by mouth for 7 days, followed by 7 days off. (Cycle length=28 days) This arm is closed.

    Drug: Atezolizumab · Drug: SY-5609 · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Divarasib + Cetuximab + FOLFOX

    Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFOX on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.

    Drug: Cetuximab · Drug: Divarasib · Drug: FOLFOX · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Divarasib + Cetuximab

    Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is active, and not recruiting participants.

    Drug: Cetuximab · Drug: Divarasib · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Divarasib + Cetuximab + FOLFIRI

    Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFIRI on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is active, and not recruiting participants.

    Drug: Cetuximab · Drug: Divarasib · Drug: FOLFIRI · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Divarasib + Bevacizumab + FOLFOX

    Participants will receive Bevacizumab 5 mg/kg by IV infusion on Days 1 and 15 and FOLFOX on Days 1 and 15 with Divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.

    Drug: Bevacizumab · Drug: Divarasib · Drug: FOLFOX · Diagnostic Test: FoundationOne®Liquid CDx

  • Experimental
    Divarasib + Bevacizumab + FOLFIRI

    Participants will receive Bevacizumab 5 mg/kg by IV infusion on Days 1 and 15 and FOLFIRI on Days 1 and 15 with Divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.

    Drug: Bevacizumab · Drug: Divarasib · Drug: FOLFIRI · Diagnostic Test: FoundationOne®Liquid CDx

Interventions

  • Inavolisib will be administered orally as per schedule specified in the respective arms.

  • Bevacizumab IV will be administered as per schedule specified in the respective arm.

    Also known as: Avastin

  • Cetuximab IV will be administered as per schedule specified in the respective arm.

  • Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.

    Also known as: Tecentriq

  • Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.

  • DrugSY-5609

    SY-5609 will be administered by mouth as per schedule specified in the respective arm.

  • Divarasib will be administered orally as per schedule specified in the respective arms.

    Also known as: GDC-6036

  • DrugFOLFOX

    FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.

  • DrugFOLFIRI

    FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.

  • Diagnostic testFoundationOne®Liquid CDx

    FoundationOne®Liquid CDx is used to identify presence of genomic alterations for participant cohort assignment.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to RECIST v1.1

    Time frame: Approximately 84 months

Secondary outcomes

  1. Duration of Response

    Defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1

    Time frame: Approximately 84 months

  2. Disease Control Rate

    Defined as the proportion of participants with stable disease, or a complete or partial response, as determined by the investigator according to RECIST v1.1

    Time frame: Approximately 84 months

  3. Percentage of Participants with Adverse Events (AEs)

    Percentage of participants with adverse events.

    Time frame: Approximately 84 months

  4. Plasma Concentrations of Divarasib

    Plasma concentration of divarasib for divarasib + cetuximab + FOLFOX, divarasib + cetuximab, and divarasib + cetuximab+ FOLFIRI, Divarasib + Bevacizumab + FOLFOX, Divarasib + Bevacizumab + FOLFIRI treatment arms.

    Time frame: At pre-defined intervals from first administration of study drug up to approximately 84 months

  5. Recommended Dose of Divarasib in Combination with Bevacizumab and FOLFOX

    Recommended dose of divarasib in combination with bevacizumab and FOLFOX based on the totality of safety, efficacy and PK data.

    Time frame: Approximately 84 months

  6. Recommended Dose of Divarasib in Combination with Bevacizumab and FOLFIRI

    Recommended dose of divarasib in combination with bevacizumab and FOLFIRI based on the totality of safety, efficacy and PK data.

    Time frame: Approximately 84 months

07

Study locations

56 of 84 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Aug 2030, 106 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 106 months is above that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 18, 2021
StartActual
Oct 22, 2021
Primary completionEst.
Aug 31, 2030
CompletionEst.
Aug 31, 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites changed recruiting status (2 now completed, 1 now withdrawn, …)
Show 4 sites
  • Mayo Clinic in Florida · Jacksonville, United StatesRecruiting→Completed
  • Hematology Oncology Salem · Salem, United StatesRecruiting→Completed
  • Irccs Istituto Nazionale Dei Tumori (Int) · Milan, ItalyRecruiting→Withdrawn
  • Mayo Clinic Arizona · Phoenix, United StatesRecruiting→Active, not recruiting
across 2 updates, Oct 9, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Mayo Clinic Arizona is now Active, not recruiting
    + 1 other change: verification date
  2. Oct 9, 2026
    3 sites changed recruiting status (2 now completed, 1 now withdrawn)
    Show 3 sites
    • Mayo Clinic in Florida · Jacksonville, United StatesRecruiting→Completed
    • Hematology Oncology Salem · Salem, United StatesRecruiting→Completed
    • Irccs Istituto Nazionale Dei Tumori (Int) · Milan, ItalyRecruiting→Withdrawn
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04929223
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Oct 22, 2021
Primary completion
Aug 31, 2030 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Reference Study ID Number: WO42758 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inavolisib · Bevacizumab · Cetuximab · Tiragolumab · Divarasib · Folfox protocol

Start the discussion